These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10072675)

  • 1. Discovery of 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)- pyridazinebutanoic acid (FK 838): a novel non-xanthine adenosine A1 receptor antagonist with potent diuretic activity.
    Akahane A; Katayama H; Mitsunaga T; Kato T; Kinoshita T; Kita Y; Kusunoki T; Terai T; Yoshida K; Shiokawa Y
    J Med Chem; 1999 Mar; 42(5):779-83. PubMed ID: 10072675
    [No Abstract]   [Full Text] [Related]  

  • 2. General pharmacology of the new non-xanthine adenosine A1 receptor antagonist (+)-(R)-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2- piperidine ethanol.
    Terai T; Kusunoki T; Kita Y; Yoshida K; Akahane A; Shiokawa Y; Kohno Y; Horiai H; Mori J; Mine Y; Kohsaka M
    Arzneimittelforschung; 1996 Feb; 46(2):185-91. PubMed ID: 8720311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel adenosine A1 receptor antagonists. Synthesis and structure-activity relationships of a novel series of 3-(2-cyclohexenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5 -a]pyridines.
    Kuroda S; Akahane A; Itani H; Nishimura S; Durkin K; Tenda Y; Sakane K
    Bioorg Med Chem; 2000 Jan; 8(1):55-64. PubMed ID: 10968264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationship of pyrazolo[3,4-d]pyrimidines: potent and selective adenosine A1 receptor antagonists.
    Poulsen SA; Quinn RJ
    J Med Chem; 1996 Oct; 39(21):4156-61. PubMed ID: 8863792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New pyrazolo[3,4-b]pyridones as selective A(1) adenosine receptor antagonists: synthesis, biological evaluation and molecular modelling studies.
    Fossa P; Pestarino M; Menozzi G; Mosti L; Schenone S; Ranise A; Bondavalli F; Trincavelli ML; Lucacchini A; Martini C
    Org Biomol Chem; 2005 Jun; 3(12):2262-70. PubMed ID: 16010360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel non-xanthine adenosine A1 receptor antagonist.
    Terai T; Kita Y; Kusunoki T; Shimazaki T; Ando T; Horiai H; Akahane A; Shiokawa Y; Yoshida K
    Eur J Pharmacol; 1995 Jun; 279(2-3):217-25. PubMed ID: 7556404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
    Tucker TJ; Sisko JT; Tynebor RM; Williams TM; Felock PJ; Flynn JA; Lai MT; Liang Y; McGaughey G; Liu M; Miller M; Moyer G; Munshi V; Perlow-Poehnelt R; Prasad S; Reid JC; Sanchez R; Torrent M; Vacca JP; Wan BL; Yan Y
    J Med Chem; 2008 Oct; 51(20):6503-11. PubMed ID: 18826204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrazolopyridines with potent activity against herpesviruses: effects of C5 substituents on antiviral activity.
    Gudmundsson KS; Johns BA; Allen SH
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1157-61. PubMed ID: 18086523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CVT-124, a novel adenosine A1 receptor antagonist with unique diuretic activity.
    Gellai M; Schreiner GF; Ruffolo RR; Fletcher T; DeWolf R; Brooks DP
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1191-6. PubMed ID: 9732378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and 3D QSAR of new pyrazolo[3,4-b]pyridines: potent and selective inhibitors of A1 adenosine receptors.
    Manetti F; Schenone S; Bondavalli F; Brullo C; Bruno O; Ranise A; Mosti L; Menozzi G; Fossa P; Trincavelli ML; Martini C; Martinelli A; Tintori C; Botta M
    J Med Chem; 2005 Nov; 48(23):7172-85. PubMed ID: 16279775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.
    Poon SF; Eastman BW; Chapman DF; Chung J; Cramer M; Holtz G; Cosford ND; Smith ND
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5477-80. PubMed ID: 15482907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of FR166124, a novel water-soluble pyrazolo-[1,5-a]pyridine adenosine A1 receptor antagonist.
    Kuroda S; Akahane A; Itani H; Nishimura S; Durkin K; Kinoshita T; Tenda Y; Sakane K
    Bioorg Med Chem Lett; 1999 Jul; 9(14):1979-84. PubMed ID: 10450966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and anti-tumor activities of some new pyridines and pyrazolo[1,5-a]pyrimidines.
    Ahmed OM; Mohamed MA; Ahmed RR; Ahmed SA
    Eur J Med Chem; 2009 Sep; 44(9):3519-23. PubMed ID: 19398146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
    Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S
    J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine antagonists: synthesis, biological evaluation, and development of an A1 bovine receptor model.
    Tuccinardi T; Schenone S; Bondavalli F; Brullo C; Bruno O; Mosti L; Zizzari AT; Tintori C; Manetti F; Ciampi O; Trincavelli ML; Martini C; Martinelli A; Botta M
    ChemMedChem; 2008 Jun; 3(6):898-913. PubMed ID: 18338422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of novel substituted 2-phenylpyrazolopyridines with potent activity against herpesviruses.
    Gudmundsson KS; Johns BA; Wang Z; Turner EM; Allen SH; Freeman GA; Boyd FL; Sexton CJ; Selleseth DW; Moniri KR; Creech KL
    Bioorg Med Chem; 2005 Sep; 13(18):5346-61. PubMed ID: 16039862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists.
    Gross RS; Guo Z; Dyck B; Coon T; Huang CQ; Lowe RF; Marinkovic D; Moorjani M; Nelson J; Zamani-Kord S; Grigoriadis DE; Hoare SR; Crowe PD; Bu JH; Haddach M; McCarthy J; Saunders J; Sullivan R; Chen T; Williams JP
    J Med Chem; 2005 Sep; 48(18):5780-93. PubMed ID: 16134945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase inhibitors. Part 6: design, synthesis, and structure-activity relationships of PDE4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory activity.
    Kojima A; Takita S; Sumiya T; Ochiai K; Iwase K; Kishi T; Ohinata A; Yageta Y; Yasue T; Kohno Y
    Bioorg Med Chem Lett; 2013 Oct; 23(19):5311-6. PubMed ID: 23988356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of C-6 substituted pyrazolo[1,5-a]pyridines with potent activity against herpesviruses.
    Allen SH; Johns BA; Gudmundsson KS; Freeman GA; Boyd FL; Sexton CH; Selleseth DW; Creech KL; Moniri KR
    Bioorg Med Chem; 2006 Feb; 14(4):944-54. PubMed ID: 16213142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrazole-based cathepsin S inhibitors with arylalkynes as P1 binding elements.
    Ameriks MK; Axe FU; Bembenek SD; Edwards JP; Gu Y; Karlsson L; Randal M; Sun S; Thurmond RL; Zhu J
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6131-4. PubMed ID: 19773165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.